What do systematic reviews say?

Intervention not reported

• Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 520 participants
  High

Intervention not reported

• Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 2203 participants
  High

Intervention not reported

• Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 117 participants
  High

Oxcarbazepine vs phenytoin

Summary of findings: oxcarbazepine leads to lower time to treatment failure due to adverse events All participants… compared with phenytoin (primary outcomes) (high certainty).

• Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only
  HR 0.22 [0.1, 0.51]
  2 studies · 480 participants
  High

Clarithromycin vs placebo

Clarithromycin showed no clear difference in number of participants with any adverse events№ of participants:… compared with placebo (low certainty).

• Medications for daytime sleepiness in individuals with idiopathic hypersomnia 2021 · Cochrane Headline outcomes only
  OR 0.41 [0.01, 12.64]
  Studies not reported
  Low

Modafinil vs placebo

Modafinil showed no clear difference in number of participants with any adverse events№ of participants:… compared with placebo (low certainty).

• Medications for daytime sleepiness in individuals with idiopathic hypersomnia 2021 · Cochrane Headline outcomes only
  OR 1.68 [0.28, 9.94]
  Studies not reported
  Low